Faisal Ghiath Sukhtian is Director at Outlook Therapeutics, Inc. (OTLK). They have made 6 open-market trades across 1 company since 2020, most recently 2026-07-29.
CIK 0001716033
6 open-market purchases totalling $239K since 2020, never a sale. Across 5 scored buys the stock is up 25.5% at ninety days, and 21.6 points ahead of the S&P over the same stretch.
6 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| OTLK | 220,972 | $108K |
Shares reported on the most recent Form 4, priced at the 2026-07-29 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 50% | 67% | 60% |
| Avg Move | +7.5% | +27.6% | +25.5% |
| Alpha | +5.9% | +24.5% | +21.6% |
| Scored | 6 | 6 | 5 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| OTLK | BUY | 2026-07-29 | 2026-07-29 | $1.05 | $100K | +17.4% | -33.9% | — |
| OTLK | BUY | 2026-05-27 | 2026-05-27 | $0.41 | $50K | +12.7% | +166.7% | -0.6% |
| OTLK | BUY | 2022-10-07 | 2022-10-11 | $1.29 | $39K | -4.8% | -16.1% | -15.3% |
| OTLK | BUY | 2021-12-02 | 2021-12-02 | $1.40 | $25K | -2.1% | +2.8% | +19.7% |
| OTLK | BUY | 2021-04-19 | 2021-04-20 | $1.82 | $18K | +25.3% | +24.2% | +23.7% |
| OTLK | BUY | 2020-09-17 | 2020-09-17 | $0.67 | $7K | -3.3% | +22.2% | +100.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.